RCT: Rucaparib vs. standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation.

Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)

Commentary: ARIEL4 Trial: Rucaparib vs Chemotherapy in Patients With Relapsed Ovarian Cancer and Deleterious BRCA1 or BRCA2 Mutations – The ASCO Post

Commentary on Twitter

In ARIEL4 phase III trial, pts with BRCA1/2-mut ovarian cancer who received ≥2 chemo regimens received rucaparib or chemo. In the ITT, mPFS was 7.4 mo vs 5.7 mo (HR 0.67, 95% CI 0.52–0.86; P = 0.0017). Three treatment-related deaths occurred w rucaparib https://t.co/G7j7djp6kV

— NatureRevClinOncol (@NatRevClinOncol) March 22, 2022